Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.60 |
| ▸ | DRD2 | P14416 | 12/20 | 0.60 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282965 | 0.92 | DRD3 (0.61) | DRD3DRD2 | |
| SCHEMBL1283284 | 0.91 | DRD3 (0.60) | DRD3DRD2AGER | |
| SCHEMBL13348991 | 0.90 | DRD3 (0.58) | DRD3DRD2AVPR1BRORCADORA3 | |
| SCHEMBL1283363 | 0.88 | DRD3 (0.62) | DRD3DRD2AGER | |
| SCHEMBL1282921 | 0.88 | DRD3 (0.55) | DRD3DRD2AGERADORA3ADORA2A | |
| SCHEMBL1283264 | 0.86 | DRD3 (0.60) | DRD3DRD2AGER | |
| SCHEMBL1283496 | 0.85 | DRD3 (0.59) | DRD3DRD2AGER | |
| SCHEMBL1284207 | 0.84 | DRD3 (0.51) | DRD3DRD2AGER | |
| SCHEMBL1283543 | 0.84 | DRD3 (0.68) | DRD3DRD2AVPR1B | |
| SCHEMBL1283458 | 0.84 | DRD3 (0.53) | DRD3DRD2AVPR1BAGER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | DRD3 4321/4885DRD2 4691/4885AVPR1B 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.